TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35005781

Group type: EXPERIMENTAL
Intervention: Systemic therapies (including pharmacological therapies, dietary supplements, and complementary and alternative medicines) for prevention of AIMSS
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Systemic therapies (including vitamin D, bionic tiger bone, Yi Shen Jian Gu granules, calcitonin) for treatment of AIMSS
Number of subjects: 2034
Study: 35005800

Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 539
Study: 35006026

Group type: EXPERIMENTAL
Intervention: Persistent or permanent AF
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 1052

Group type: COMPARATOR
Intervention: First diagnosed AF
Number of subjects: 1052
Study: 35007144

Group type: EXPERIMENTAL
Intervention: Naive T-Cell Depletion
Number of subjects: 138
Study: 35007224

Group type: EXPERIMENTAL
Intervention: Groin hernia surgery in women
Number of subjects: 4021
Study: 35007270

Group type: EXPERIMENTAL
Intervention: Robotic resection using the da Vinci Xi system with intraoperative neurostimulation mapping
Number of subjects: 3
Study: 35007329

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional glycemic control
Number of subjects: 1441
Study: 35007745

Group type: EXPERIMENTAL
Intervention: Hazelnut oral immunotherapy (H-OIT)
Number of subjects: 70
Study: 35007813

Group type: EXPERIMENTAL
Intervention: Healthy Nordic Diet (HND)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Diet (CD)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Urine metabolite profiles
Number of subjects: 200
Study: 35008361

Group type: EXPERIMENTAL
Intervention: Machine Learning-based prognostic model (eMIPI)
Number of subjects: 300
Study: 35010554

Group type: EXPERIMENTAL
Intervention: Modified kangaroo care lateral position
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional kangaroo care prone position
Number of subjects: 70
Study: 35010773

Group type: EXPERIMENTAL
Intervention: Exposure to greenness (measured using NDVI)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Exposure to passive smoke during pregnancy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Crowding index
Number of subjects: 179
Study: 35010948

Group type: EXPERIMENTAL
Intervention: Dietary macronutrients intake (total fat, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Total protein consumption
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Physical activity (work/school and leisure time)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PA intensity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Diet and PA
Number of subjects: 96
Study: 35011021

Group type: EXPERIMENTAL
Intervention: Increased negative mood
Number of subjects: 94
Study: 35011752

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture therapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 101
Study: 35011768

Group type: EXPERIMENTAL
Intervention: Luspatercept + Best Supportive Care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Best Supportive Care (BSC)
Number of subjects: 0
Study: 35011838

Group type: EXPERIMENTAL
Intervention: Leucine-enriched whey protein supplementation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 35011862

Group type: EXPERIMENTAL
Intervention: MAGGIC score
Number of subjects: 1089
Study: 35012012

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 244

Group type: COMPARATOR
Intervention: No-CPAP
Number of subjects: 244
Study: 35012015

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Pre-admission stroke risk scores
Number of subjects: 501
Study: 35012490

Group type: EXPERIMENTAL
Intervention: ITIP3 (severe pneumonia and/or selected comorbidities)
Number of subjects: 83

Group type: COMPARATOR
Intervention: ITIP1 (non-severe pneumonia)
Number of subjects: 83

Group type: COMPARATOR
Intervention: ITIP2 (non-severe pneumonia)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clinically cured children
Number of subjects: 83

Group type: COMPARATOR
Intervention: Not clinically cured children
Number of subjects: 83
Study: 35012530

Group type: EXPERIMENTAL
Intervention: Greater study staff change frequency
Number of subjects: 5579

Group type: EXPERIMENTAL
Intervention: Staff consistency
Number of subjects: 5579

Group type: EXPERIMENTAL
Intervention: Parent accuracy about child's type 1 diabetes risk
Number of subjects: 5579

Group type: EXPERIMENTAL
Intervention: Parent beliefs that something can be done to reduce child's risk
Number of subjects: 5579

Group type: EXPERIMENTAL
Intervention: Higher education levels and higher depression scores
Number of subjects: 5579
Study: 35012566

Group type: EXPERIMENTAL
Intervention: Supportive intervention for family caregivers (FCs) of HSCT patients
Number of subjects: 154
Study: 35012570

Group type: EXPERIMENTAL
Intervention: Choizitaconso therapeutic patient education programme
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not enrolled in Choizitaconso)
Number of subjects: 90
Study: 35012606

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without awake prone positioning
Number of subjects: 0
Study: 35012620

Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 720
Study: 35012623

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 120
Study: 35012628

Group type: EXPERIMENTAL
Intervention: PATHWEIGH
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 57
Study: 35012646

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 912
Study: 35012889

Group type: EXPERIMENTAL
Intervention: VPM1002BC (intravesical treatment, 6 weekly instillations followed by maintenance for 1 year)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: VPM1002BC (intravesical treatment)
Number of subjects: 40
Study: 35012890

Group type: EXPERIMENTAL
Intervention: MPS I (both MPS IA and MPS IH)
Number of subjects: 61
Study: 35012901

Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 80
Study: 35012960

Group type: EXPERIMENTAL
Intervention: New generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer
Number of subjects: 37198

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37198
Study: 35013314

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dual HER2-block (trastuzumab and pertuzumab) and palbociclib without fulvestrant
Number of subjects: 0
Study: 35013456

Group type: EXPERIMENTAL
Intervention: ssCART-19 treatment in low tumor burden group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ssCART-19 treatment in high tumor burden group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ssCART-19 treatment
Number of subjects: 78
Study: 35014000

Group type: EXPERIMENTAL
Intervention: Pre-intervention average noise levels during induction
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Post-intervention average noise levels during induction
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Pre-intervention peak noise levels during induction
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Post-intervention peak noise levels during induction
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Post-intervention anesthesiologist satisfaction
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Pre-intervention patient satisfaction
Number of subjects: 309
Study: 35014537

Group type: EXPERIMENTAL
Intervention: mp-MRI guided core biopsy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PTEN deletion and Ki-67 expression analysis
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiotherapy
Number of subjects: 19
Study: 35014900

Group type: EXPERIMENTAL
Intervention: Reduced-dose deep learning image reconstruction (DLIR)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard-dose filtered back projection (FBP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both reduced-dose DLIR and standard-dose FBP
Number of subjects: 51
Study: 35014972

Group type: EXPERIMENTAL
Intervention: Supportive text messages (Text4Support)
Number of subjects: 181
Study: 35015056

Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DDS) assessment
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (DDS) subscales
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Factors associated with high distress
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Multivariate analyses
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms
Number of subjects: 438
Study: 35015137

Group type: EXPERIMENTAL
Intervention: Distance to first symptoms (DTFS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Time to first symptoms (TTFS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 6-min walking distance (6WD)
Number of subjects: 49
Study: 35015817

Group type: EXPERIMENTAL
Intervention: Early rapid eGFR loss (slope ≤-3% per year)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: No early rapid eGFR loss (slope >-3% per year)
Number of subjects: 1441
Study: 35015819

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks for up to 16 cycles) and Rituximab (375 mg/m2 IV weekly for 4 weeks in cycle 1 only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Rituximab
Number of subjects: 30
Study: 35015828

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Damage by SLICC-Damage Index
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Hypocomplementemia in the first trimester
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 238
Study: 35015837

Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer (FET)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer (Fresh-ET)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Naturally conceived (NC) children
Number of subjects: 150
Study: 35015869

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention including training for health-care providers, interpersonal communication, mobile phone support, and mass media messaging
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 1200
Study: 35015879

Group type: EXPERIMENTAL
Intervention: 15 g GOS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 g FOS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 g acacia gum
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6.1 g lactose and 1.5 g sucrose (control)
Number of subjects: 30
Study: 35015980

Group type: EXPERIMENTAL
Intervention: Daily exposure to mild intermittent hypoxia
Number of subjects: 0
Study: 35016146

Group type: EXPERIMENTAL
Intervention: Oral D/L-Na-lactate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous iso-lactemic D/L-Na-lactate
Number of subjects: 10
Study: 35016636

Group type: EXPERIMENTAL
Intervention: STOPP/START criteria version 2
Number of subjects: 740
Study: 35016694

Group type: EXPERIMENTAL
Intervention: Gesture movements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Grasp movements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Increased impairment level
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Reaching distally
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Reaching proximally
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Consistent metric relations during reaching distally
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Spatiotemporal differences
Number of subjects: 31
Study: 35017097

Group type: EXPERIMENTAL
Intervention: Rural cancer survivors (specifically those in isolated, small, rural towns)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black cancer survivors
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Non-Hispanic White cancer survivors
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Rural-Urban Commuting Area categorizations A and E
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Overall V&F consumption
Number of subjects: 731
Study: 35017151

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and decitabine
Number of subjects: 10
Study: 35017154

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily)
Number of subjects: 37
Study: 35017197

Group type: EXPERIMENTAL
Intervention: Biotin and prebiotic supplementation in high-fat diet-fed mice
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Antibiotic treatment in mice
Number of subjects: 1545
Study: 35017229

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity levels measured using the General Practice Physical Activity Questionnaire (GPPAQ)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Self-efficacy for exercise measured with Bandura's Self-Efficacy for Exercise Scale
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Qualitative analysis through semistructured interviews and focus groups
Number of subjects: 84
Study: 35017248

Group type: EXPERIMENTAL
Intervention: Investigational MCPM technologies from EarlySense and Sibel
Number of subjects: 27
Study: 35017251

Group type: EXPERIMENTAL
Intervention: Patients with HSP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy individuals (control)
Number of subjects: 200
Study: 35017298

Group type: EXPERIMENTAL
Intervention: hiPSC-derived neurons from individuals with high PRS for schizophrenia
Number of subjects: 28

Group type: COMPARATOR
Intervention: hiPSC-derived neurons from neurotypical individuals with low PRS
Number of subjects: 28
Study: 35017496

Group type: EXPERIMENTAL
Intervention: molBV score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternate inflammatory BV signature (elevated TNF-α/MIP-1β ratio)
Number of subjects: 0
Study: 35017568

Group type: EXPERIMENTAL
Intervention: Prone setup
Number of subjects: 146

Group type: COMPARATOR
Intervention: Supine setup
Number of subjects: 146
Study: 35017581

Group type: EXPERIMENTAL
Intervention: Tourniquet deflation
Number of subjects: 20
Study: 35018097

Group type: EXPERIMENTAL
Intervention: mirtazapine/SNRIs
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: mirtazapine/SNRIs+CBT
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: mirtazapine+SNRIs
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: mirtazapine+SNRIs+physical therapies
Number of subjects: 107
Study: 35018342

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Therapy (VNS Therapy)
Number of subjects: 823
Study: 35018346

Group type: EXPERIMENTAL
Intervention: IV vasoactive intestinal peptide
Number of subjects: 1
Study: 35018370

Group type: EXPERIMENTAL
Intervention: Engage-PA (two 60-minute telephone sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual plus fitness tracker (TAU+)
Number of subjects: 40
Study: 35018442

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2800 IU to 7000 IU daily for 3-9 months)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 260
Study: 35018553

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (QD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg QD
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lorlatinib 75 mg QD
Number of subjects: 29
Study: 35018639

Group type: EXPERIMENTAL
Intervention: Any exercise training for two to 12 months
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Any exercise training for three to 12 months
Number of subjects: 4291

Group type: EXPERIMENTAL
Intervention: Any exercise training for two to six months
Number of subjects: 4291
Study: 35018878

Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulant within four days of stroke onset
Number of subjects: 3478

Group type: COMPARATOR
Intervention: Delayed initiation of direct oral anticoagulant, 7 to 14 days from onset
Number of subjects: 3478

Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulant
Number of subjects: 3478

Group type: COMPARATOR
Intervention: Delayed initiation of direct oral anticoagulant
Number of subjects: 3478
Study: 35019770

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 35019846

Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Number of subjects: 100
Study: 35019850

Group type: EXPERIMENTAL
Intervention: QPL intervention group (patients with MBC or MUM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: QPL-naive historical control group
Number of subjects: 80
Study: 35020119

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 541
Study: 35020185

Group type: EXPERIMENTAL
Intervention: Opioid taper
Number of subjects: 7
Study: 35020672

Group type: EXPERIMENTAL
Intervention: ECMO support for COVID-19 ARDS
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (ECMO support for viral non-COVID-19 ARDS)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Adjusted subhazard ratio for ICH in COVID-19 group
Number of subjects: 210
Study: 35020756

Group type: EXPERIMENTAL
Intervention: PBSF Guidelines (standard-of-care)
Number of subjects: 0
Study: 35020854

Group type: EXPERIMENTAL
Intervention: PBMC FGL2/IFNG biomarker positive patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) withdrawal in patients with normal liver biopsies
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Liver gene ratio of FOXP3/IFNG ≥ 1 prior to IS withdrawal
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Increased CD4+ T regulatory T cells
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Gene expression analysis in pre-withdrawal liver biopsies
Number of subjects: 69
Study: 35020917

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal during exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 40
Study: 35021220

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood (UCB) from newborns exposed to maternal EP anemia
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (UCB from newborns of non-anemic mothers)
Number of subjects: 98
Study: 35021863

Group type: EXPERIMENTAL
Intervention: Hepatic irradiation with Yttrium-90 microspheres followed by immunotherapy with Ipilimumab and Nivolumab
Number of subjects: 0
Study: 35021890

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35022035

Group type: EXPERIMENTAL
Intervention: Monocyte-Derived Dendritic-cell Therapy (MDDCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 35022086

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz over the right DLPFC, 2000 pulses per day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 144
Study: 35022159

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2 vaccine
Number of subjects: 64
Study: 35022299

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1227
Study: 35022304

Group type: EXPERIMENTAL
Intervention: Regular physical activity and moderate to vigorous exercise levels
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: High regular physical activity levels and exercise habits
Number of subjects: 237
Study: 35022321

Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally weekly) in arm A (PC-PG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally weekly) in arm B (other neuroendocrine tumors)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ONC201 (625 mg orally on 2 consecutive days each week) in arm C (PC-PG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Karnofsky performance status
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment-related adverse events
Number of subjects: 30
Study: 35022322

Group type: EXPERIMENTAL
Intervention: oHSV treatment with NOTCH blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: oHSV treatment
Number of subjects: 0
Study: 35022448

Group type: EXPERIMENTAL
Intervention: ImmTOR (biodegradable nanoparticles-encapsulating rapamycin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pegadricase (an immunogenic, pegylated uricase enzyme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ImmTOR and pegadricase combination
Number of subjects: 0
Study: 35022711

Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Absence of SARS-CoV-2 antibodies
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Higher levels of viral RNA
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Fewer days since symptom onset
Number of subjects: 204
Study: 35022790

Group type: EXPERIMENTAL
Intervention: Early treatment with ACE inhibitors (ACEis)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Untreated hemizygous patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Very late treated hemizygotes
Number of subjects: 114

Group type: COMPARATOR
Intervention: Untreated heterozygotes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Treated heterozygous females
Number of subjects: 114
Study: 35023065

Group type: EXPERIMENTAL
Intervention: Seed-based resting-state functional connectivity (RsFc) analysis using three cerebellar regions of interest (ROIs)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 247
Study: 35023343

Group type: EXPERIMENTAL
Intervention: Large-bore transradial access (TRA)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Large-bore transfemoral access (TFA)
Number of subjects: 343